Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu-OncoACP3
- Development stage
- Unknown
- Lead developer
- Philochem
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Lu-OncoACP3 (also known as 177Lu-OncoACP3 or Lu-RYZACP3) is a clinical-stage radiopharmaceutical therapeutic agent targeting prostatic acid phosphatase (ACP3) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Developed by Philochem (a subsidiary of Philogen) and licensed to RayzeBio (a Bristol Myers Squibb company), the drug consists of a high-affinity small-molecule organic ligand targeting ACP3, an innovative spacer structure, and a DOTAGA chelator complexed with the beta-emitting radioisotope Lutetium-177 (177Lu). ACP3 is highly and selectively expressed in prostate cancer cells with minimal expression in normal tissues, offering a promising alternative target for patients with low or heterogeneous PSMA expression. Upon binding to ACP3, the radioligand delivers localized, cytotoxic beta radiation to tumor cells, inducing DNA damage and cell death.
- Other names
- [177Lu]Lu-OncoACP3[177Lu]Lu-OncoACP3-DOTA[177Lu]Lu-RYZACP3[177Lu]Lu-RYZACP3-DOTALu-ACP3Lu-ACP-3Lu-ACP 3
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on Lu-OncoACP3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu-OncoACP3.